Plain-English translation of NCT06215716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people with fatty liver disease that has progressed to scarring (called fibrosis). Researchers want to know whether this new medication, given as a weekly injection, can reduce liver scarring and improve liver health. About 1,650 people will participate over roughly 5 years.
Fatty liver disease is becoming very common, and many people develop dangerous scarring over time that can lead to liver failure. Right now, there are very few treatment options available, so doctors urgently need new medications to slow or reverse the damage before it becomes irreversible.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for screening, then receive weekly injections of either the new medication (at one of two doses) or a placebo for up to one year or more. During this time, you'll have regular clinic visits for blood work, imaging tests, and possibly repeat liver biopsies to check how well the treatment is working. The entire study commitment is approximately 5 years, though most active treatment happens in the first year to two years.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States